Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic
has led to the development of various vaccines. Real-life data on immune responses elicited …

Abstract In December 2020, COVID-19 vaccination started in many countries, with which the
world community hopes to stop the further spread of the current pandemic. More than 90% of …

Introduction Older adults are subject to higher COVID-19 infection and mortality rates. Safety
and immunogenicity of MVC-COV1901, a protein subunit vaccine have been demonstrated …

Introduction There is a need for automated, high-throughput assays to quantify immune
response after SARS-CoV-2 vaccination. This study assessed the combined utility of the …

Purpose Residents in nursing homes for the elderly (NH) are at high risk for death from
COVID-19. We investigated whether repeated non-mandatory RT-PCR SARS-CoV-2 …

Introduction: COVID-19 vaccine have been indicated to successfully decrease the hazard for
symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …

Objectives We evaluated the IgG antibody titer against SARS-CoV-2 in 196 residents of a
Spanish nursing home after the second dose of the BNT162b2 vaccine and the evolution of …

We provide follow-up data on the humoral immune response after COVID-19 vaccinations of
two distinct cohorts aged below 60 and over 80 years to screen for age-related differences in …

Background: Mortality rate of COVID-19 infection isexceptionally high in the older
population. Various vaccines are being rapidly developed as an attempt to halt the …

Background: In order to tackle COVID-19 pandemic and the emerging variants, researchers
around the globe have investigated many vaccine candidates from different manufacturers …